Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Sep 1;25(9):3315-3325.
doi: 10.31557/APJCP.2024.25.9.3315.

Correlation of CD 133 Biomarker with Outcomes and Therapy Response in Advanced-Stage Non-Small Cell Lung Carcinoma

Sri Mayasari  1   2 , Arif Santoso  1   2 , Irawaty Djaharuddin  1   2 , Harun Iskandar  1   2 , Nurjannah Lihawa  1   2 , Harry Akza Putrawan  1   2 , Imam Nurjaya  1   2 , Rasiha Rasiha  1   2
Affiliations
Observational Study

Correlation of CD 133 Biomarker with Outcomes and Therapy Response in Advanced-Stage Non-Small Cell Lung Carcinoma

Sri Mayasari et al. Asian Pac J Cancer Prev. .

Abstract

Objective: This study aimed to analyze CD 133 stem cell biomarker levels in serum and bronchial lavage, as well as correlate these levels with treatment responses and outcomes in patients with advanced-stage NSCLC.

Methods: This is a cross-sectional, observational, and analytical study that analyzed data from NSCLC patients and control at Dr. Wahidin Sudirohusodo Hospital, Makassar. CD 133 levels in serum and bronchial lavages were quantified using ELISA and correlated with treatment responses assessed by RECIST 1.1 criteria.

Result: A total of 118 participants were used, with 66 being NSCLC patients and 52 as the control. The results showed significant differences in CD 133 serum and bronchial lavage levels (p<0.05). Moreover, NSCLC patients with advanced tumors (T4) had higher CD 133 levels in bronchial wash (p<0.05). The bronchial wash CD 133 test showed higher sensitivity (83.6%) and specificity (79.2%) compared to serum CD 133. Even though CD 133 levels were not significantly correlated with treatment response, they were higher in patients with advanced tumor stages.

Conclusion: CD 133 levels were significantly higher in bronchial wash samples from NSCLC patients with advanced tumors (T4). Also, there was a positive correlation between CD 133 levels in bronchial wash and serum. These results emphasized the potential of CD 133, particularly in bronchial wash, as a valuable diagnostic tool for NSCLC.

Keywords: Bronchial lavage; CD 133; RECIST; non-small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declared that there are no conflicts of interests or personal relationships that could have influenced the work presented in this paper.

Figures

Figure 1
Figure 1
Study Flow Chart
Figure 2
Figure 2
ROC Curve of Bronchial Wash CD 133 and Serum CD 133
Figure 3a
Figure 3a
Survival Analysis based on Cell Type in NSCLC Patients
Figure 3b
Figure 3b
Survival Analysis based on Cancer Stage in NSCLC Patients
Figure 3c
Figure 3c
Survival Analysis based on Performance Status in NSCLC Patients
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. - PubMed
    1. Febriani A, Furqon A. Metastasis kanker paru. J Respirasi. 2020;4:94 .
    1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 - PubMed
    1. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell. 2009;138(5):822–9. - PubMed
    1. Schmohl JU, Vallera DA. Cd133, selectively targeting the root of cancer. Toxins (Basel) 2016;8:6. - PMC - PubMed

Publication types

MeSH terms